As supportive evidence, SLX4 PGV carriers among high‐grade serous ovarian cancer patients have an odd ratio of 4.07,30 and the SLX4 p.A938Tfs*7 germline variant has been previously identified in prostate cancer.31 Here, SLX4 is linked to prostate carcinoma.